NASDAQ:XBIT XBiotech Q3 2026 Earnings Results & Report $1.78 -0.07 (-3.78%) Closing price 04:00 PM EasternExtended Trading$1.77 -0.01 (-0.56%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. XBiotech missed analyst earnings expectations in its Q3 2026 results, released November 12, 2026. The company reported EPS of -$0.15 versus the $0.02 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 12, 2026TimeBefore Market Opens XBiotech EPS ResultsActual EPS-$0.15Consensus EPS $0.02Beat/MissMissed by -$0.17One Year Ago EPSN/AXBiotech Revenue ResultsActual RevenueN/AExpected Revenue$7 millionBeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesSEC FilingEarnings HistoryCompany Profile XBiotech Q3 2026 Earnings FAQ Did XBiotech beat earnings estimates for Q3 2026? XBiotech (NASDAQ:XBIT) reported earnings of -$0.15 per share for Q3 2026, missing the consensus estimate of $0.02. The report was announced on Thursday, November 12, 2026. XBiotech Earnings HeadlinesXBiotech Inc.: XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive OfficersOctober 23, 2026 | finanznachrichten.deXBiotech Appoints Jan-Paul Simard as Co-Chief Executive Officer Alongside Dr. Sushma ShivaswamyOctober 23, 2026 | quiverquant.comQWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 17 at 1:00 AM | Base Camp Trading (Ad)XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive OfficersOctober 23, 2026 | globenewswire.comXBiotech Inc.: XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal CancerOctober 19, 2026 | finanznachrichten.deXBiotech's TASKIN Trial Meets Primary Efficacy Criterion In Metastatic Colorectal CancerOctober 19, 2026 | rttnews.comSee More XBiotech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like XBiotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XBiotech and other key companies, straight to your email. Email Address About XBiotechXBiotech (NASDAQ:XBIT) is a biopharmaceutical company based in Austin, Texas, that discovers and develops antibody-based therapies. Its approach uses “True Human” antibodies derived from naturally occurring human immune responses, with the goal of developing treatments for serious diseases. The company’s research has included antibody candidates for cancer and inflammatory conditions. One of its best-known candidates is bermekimab, an antibody that targets interleukin-1 alpha, a protein involved in inflammation. XBiotech has also pursued other therapeutic programs as part of its drug-development work. Founded in 2005, XBiotech conducts research and clinical development to advance its antibody therapies. John Simard founded the company and has served as its chief executive officer.View XBiotech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to WatchTyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend InvestorsMongoDB's Biggest Advantage May Be GitLab's Biggest WeaknessMicrosoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be BuildingTyson Foods' 10% Surge Puts a Breakout in Sight, But Wall Street Remains CautiousOndas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog? Upcoming Earnings Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.